Home
Posts
With MFN Deals in the Rear-View Mirror, Pharma CEOs at JPM Say They Can ‘Focus More on the Fundamentals’

With MFN Deals in the Rear-View Mirror, Pharma CEOs at JPM Say They Can ‘Focus More on the Fundamentals’

And a new resource from J&J underscores the need to protect the U.S. patent system

Jan 14, 2026

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found